Today's Daily Dose brings you news about Antibe's safety study results of ATB-346; Immunovaccine's upcoming clinical trial catalysts; Chiasma's progress in the development of octreotide capsules in the treatment of acromegaly; KemPharm's pharmacokinetic study with a KP415/d-methylphenidate in ADHD and NovaBay's strong financial performance.
from RTT - Biotech http://ift.tt/2FSIsUf
via IFTTT
No comments:
Post a Comment